Matching trials
1,853 results
- IPASSIndependent statistical analysis of the randomized phase 3 IPASS trial of gefitinib versus carboplatin/paclitaxel in non-small cell lung cancer, including trial design, progression-free survival, planned statistical methods, safety, and interpretation.
- IPATunity130Independent statistical analysis of A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer:…
- IPERGAYIndependent statistical analysis of IPERGAY, a phase 3 randomized trial evaluating on-demand antiretroviral pre-exposure prophylaxis for HIV infection prevention in men who have sex with men.
- IRISAn independent statistical analysis of the randomized phase 3 IRIS trial evaluating Follitropin Delta (FE 999049) versus Follitropin Alfa (GONAL-F) for controlled ovarian stimulation in Indian women with infertility.
- IRISComplete statistical analysis of the IRIS trial of pioglitazone versus placebo after stroke or myocardial infarction, including trial design, time-to-event endpoints, Cox modeling, mixed-effects analysis, multiplicity, interim analysis, results, and statistical interpretation.
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA): Complete Statistical AnalysisIndependent statistical analysis of Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth: Complete Statistical AnalysisIndependent statistical analysis of Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02224625).
- ISABELA1Independent statistical analysis of A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care: primary endpoint results,…
- ISABELA2Independent statistical analysis of A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care: primary endpoint results,…
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ITPIndependent statistical analysis of Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00699140).
- IV APAP SFIndependent statistical analysis of Analgesic Efficacy of Repeated Doses of Intravenous (IV) Acetaminophen in Post-operative Pediatric Spine Fusion Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- JACOBIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer: primary endpoint…
- JADE TEENIndependent statistical analysis of JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Japanese IP-TN Trial: Complete Statistical AnalysisIndependent statistical analysis of Japanese IP-TN Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02831569).
- JAVELIN Bladder 100A detailed statistical analysis of the randomized phase 3 JAVELIN Bladder 100 trial of avelumab plus best supportive care versus best supportive care in patients with urothelial cancer, including trial design, time-to-event…
- JAVELIN Ovarian 100Independent statistical analysis of JAVELIN Ovarian 100, the phase 3 trial of avelumab-based strategies in previously untreated epithelial ovarian cancer, including progression-free survival, overall survival, statistical methodology, safety, and interpretation.
- JMDBAn independent statistical analysis of the randomized phase 3 JMDB trial of pemetrexed and cisplatin versus gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
- JPN ATO OLEIndependent statistical analysis of A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- JUNIPERIndependent statistical analysis of Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144: primary endpoint results, effect estimate with confidence interval, sample-size…
- KarMMa-3Independent statistical analysis of the randomized phase 3 KarMMa-3 trial of bb2121 versus standard regimens in relapsed and refractory multiple myeloma, including its progression-free survival endpoint, trial design, statistical methodology, and planned…
- KEEPsAKE 1Independent statistical analysis of A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease…
- KETAMINEIndependent statistical analysis of Administration of Ketamine to Prevent the Post-operative Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00210210).
- Ketamine Patient-Controlled Analgesia for Acute Pain: Complete Statistical AnalysisIndependent statistical analysis of Ketamine Patient-Controlled Analgesia for Acute Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02062879).
- Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.: Complete Statistical AnalysisIndependent statistical analysis of Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- KEYNOTE-010Independent statistical analysis of KEYNOTE-010, including its randomized phase 2/3 design, overall survival, progression-free survival, response, safety, statistical methods, and interpretation.
- KEYNOTE-040Independent statistical analysis of KEYNOTE-040, a randomized phase 3 trial of pembrolizumab versus standard treatment for recurrent or metastatic head and neck squamous cell cancer, including overall survival, progression-free survival, response, statistical…
- KEYNOTE-054Independent statistical analysis of KEYNOTE-054, a randomized phase 3 trial of pembrolizumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-189Independent statistical analysis of KEYNOTE-189 (NCT02578680), a randomized phase 3 trial evaluating pembrolizumab with pemetrexed-platinum chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
- KEYNOTE-240Independent statistical analysis of KEYNOTE-240, a randomized phase 3 trial of pembrolizumab plus best supportive care versus placebo plus best supportive care in previously systemically treated advanced hepatocellular carcinoma.
- KEYNOTE-394Independent statistical analysis of KEYNOTE-394, a randomized phase 3 trial of pembrolizumab or placebo with best supportive care in Asian participants with previously treated advanced hepatocellular carcinoma.
- KEYNOTE-522Independent statistical analysis of KEYNOTE-522, a randomized phase 3 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab versus placebo as adjuvant therapy in triple-negative breast cancer.
- KEYNOTE-564Independent statistical analysis of KEYNOTE-564, a randomized phase 3 trial of pembrolizumab versus placebo in the adjuvant treatment of renal cell carcinoma after nephrectomy, including disease-free survival, trial design, statistical methodology, and…
- KEYNOTE-671Independent statistical analysis of KEYNOTE-671, a randomized phase 3 trial of pembrolizumab with platinum-doublet chemotherapy as neoadjuvant/adjuvant therapy for resectable stage II, IIIA, and resectable IIIB non-small cell lung cancer.
- KEYNOTE-756Independent statistical analysis of KEYNOTE-756, a randomized phase 3 trial evaluating pembrolizumab versus placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy in early-stage ER+/HER2- breast cancer.
- KEYNOTE-A18Independent statistical analysis of KEYNOTE-A18 (NCT04221945), a randomized phase 3 trial of chemoradiotherapy with or without pembrolizumab in locally advanced cervical cancer, including primary time-to-event results, secondary endpoints, cLDA, stratified analysis, and…
- KOMETIndependent statistical analysis of Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- KRYSTAL-10Independent statistical analysis of KRYSTAL-10, a randomized phase 3 study of MRTX849 with cetuximab versus chemotherapy in patients with advanced colorectal cancer with KRAS G12C mutation.
- KRYSTAL-12Independent statistical analysis of KRYSTAL-12, the phase 3 randomized trial of adagrasib versus docetaxel in patients with advanced non-small cell lung cancer with a KRAS G12C mutation.
- LADIIIndependent statistical analysis of Labor and Delivery Implant Insertion: A Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02866643).
- Lamotrigine Extended-Release In Elderly Patients With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Lamotrigine Extended-Release In Elderly Patients With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00516139).
- Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients: Complete Statistical AnalysisIndependent statistical analysis of Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00383708).
- LANTERNIndependent statistical analysis of Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly: primary endpoint results, effect estimate with confidence interval,…
- LAP07Independent statistical analysis of LAP07, a phase 3 randomized trial evaluating gemcitabine-based treatment strategies and radiation therapy or erlotinib in locally advanced pancreatic cancer.
- LASORIndependent statistical analysis of Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A: Complete Statistical AnalysisIndependent statistical analysis of Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.: Complete Statistical AnalysisIndependent statistical analysis of LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LCIOADMT2Independent statistical analysis of Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…